AVAravind Viswanathan

Aravind Viswanathan

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aravind Viswanathan has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Machine-Learning Model Identifies New Diagnostic Criteria for Beckwith-Wiedemann Spectrum

    by Sylvie A. Adams, Aravind Viswanathan, Bamelak T. Duki, Andrew M. George, Jill A. Fahrner, Darko Stefanovski, Christopher M. Cielo, Jennifer M. Kalish

    Objective: Beckwith-Wiedemann spectrum (BWSp) is an overgrowth and cancer predisposition disorder caused by genetic and epigenetic alterations of chromosome 11p15. The 2018 international consensus produced a clinical scoring system to capture the phenotypic variability of BWSp and guide genetic testing and clinical management, including tumor screening, in patients without molecular confirmation. In this study, we evaluated BWSp predictors to identify the most informative features. Methods: Supervised machine learning analyzed 25 phenotypic features in 555 patients with BWSp and 150 controls. Logistic regression, combined with a purposeful stepwise selection algorithm, identified a subset of features that can accurately classify subjects. Model performance was evaluated in a testing set and validated externally. Results: The final model included six predictors: macroglossia, lateralized overgrowth, midface flattening, hepatomegaly, omphalocele, and developmental delay. Developmental delay was the only negative predictor; macroglossia (OR 46.10) and lateralized overgrowth (OR 27.87) were the strongest predictors. The proposed model and 2018 system did not differ in classification performance for testing ( P = .39) or external ( P = .15) sets. Conclusion: A simplified diagnostic model, driven by macroglossia and lateralized overgrowth, differentiates between patients with BWSp and controls with performance comparable to the 2018 system. And may help physicians prioritize BWSp evaluation.

  • Open Access

    High‐Resolution Genomic Characterization of WAGR Spectrum Disorder: Insights From a Novel Cohort and Literature Synthesis, and Validation of Patient‐Reported Data

    by Andrew M. George, Bamelak T. Duki, Zoe S. Katz, Aravind Viswanathan, Suzanne P. MacFarland, Evan R. Hathaway, Caitlin Monahan, John Morris, Kelly L. Trout, Shari M. Krantz, et al.

    WAGR spectrum disorder (WAGRSD) is an ultra‐rare congenital disorder caused by heterozygous deletion of chromosome 11p13. While classically associated with Wilms tumor, Aniridia, Genitourinary anomalies, and a Range of developmental delays, accurate delineation of the deletion is critical for prognosis because the phenotypic spectrum extends well beyond this tetrad. To improve diagnostic resolution, we developed and validated a high‐density custom CGH–SNP array for precise breakpoint mapping of 11p13. We present a molecularly confirmed cohort of 23 new patients and integrate these with 91 published cases, forming the largest combined cohort to date ( N = 114) with detailed genotype–phenotype information. Key findings include: (1) the custom array provided superior genomic resolution compared to standard clinical arrays; (2) seven patients (6.1%) were found to have a dual diagnosis of WAGRSD and Potocki‐Shaffer syndrome (PSS)—a contiguous‐gene syndrome characterized by multiple osteochondromas that requires distinct surveillance; (3) in 42 patients with fully defined deletions ( n = 42, 38% of the cohort), no statistically significant association was observed between deletion of LMO2 (or other candidate genes) and Wilms tumor risk; and (4) phenotypic frequencies in this medically validated cohort closely aligned with prior caregiver‐reported registry data, validating patient‐driven registries as a reliable resource for rare disease research. Together, these findings underscore the necessity of high‐resolution genomic testing to guide counseling, refine anticipatory management—including screening for PSS‐related complications—and expand the phenotypic understanding of 11p13 deletion disorders.


  • Open Access

    Determinants of hyperinsulinism severity in children with Beckwith-Wiedemann syndrome

    by Andrew M George, Aravind Viswanathan, Jonathan H Sussman, Evan R Hathaway, Abigail Casalnova, Salima Nesbitt, Kara E Boodhansingh, Nicole M Stewart, Heather J McKnight, Katherine Lord, et al.

    Context: Congenital hyperinsulinism (HI) is a serious clinical feature of Beckwith-Wiedemann syndrome (BWS) causing severe hypoglycemia. The relationship between BWS genotypes and HI severity is not well understood. Objective: Investigate the relationship between molecular determinants of patients with BWS and HI with measures of HI severity. Methods: This retrospective cohort study included 85 children from 2009-2024, all patients evaluated at single, tertiary care center. BWS genotype frequency included 41 children with pUPD11, 24 with IC2 LOM, 8 with 11p15 chromosomal anomalies, 6 with GWpUPD, 4 with IC1 GOM, and 2 with CDKN1C. Retrospectively reviewed interventions included maximum glucose infusion rate (max GIR), diazoxide responsiveness, and surgery. Primary outcome was association between BWS genotypes and measures of HI severity. Secondary outcomes included the relationship between pUPD11 length and presence of KATP variants with diazoxide responsiveness and surgical need. Results: Significant differences presented among genotypes in max GIR (P = .004), enteral dextrose requirements (P = .029), and pancreatectomy (P = .012). Most patients with IC2 LOM, IC1 GOM or CDKN1C were diazoxide responsive and did not require surgery. Patients with pUPD11 were more likely to be diazoxide unresponsive and to require surgery, especially if pUPD11 length extended into the KATP gene region and if a pathogenic variant in the ABCC8 or KCNJ11 was present. Conclusion: Patients with pUPD11 experience more severe HI, while patients with IC2 LOM, IC1 GOM, and CDKN1C exhibit milder disease. Based on our findings, we designed a genetic testing algorithm to guide clinical management.


  • Open Access

    The Behavioral Phenotype and Importance of Multidisciplinary Care in Patients With Sotos Syndrome: A Single‐Center Experience

    by Aravind Viswanathan, Andrew M. George, Evan R. Hathaway, Carlyn Glatts, Jennifer M. Kalish

    Sotos syndrome is an autosomal dominant condition caused by pathogenic variants in the NSD1 gene on chromosome 5q35. It is characterized by macrosomia, distinctive facial features, and developmental delays. Patients are also reported to have a behavioral phenotype including autism spectrum disorder, attention deficit/hyperactivity disorder, anxiety, and increased rates of tantrums and aggressive behavior. Here, we introduce and phenotype a novel cohort of 25 patients with molecularly confirmed Sotos syndrome. We also present the detailed behavioral histories of two patients and provide guidance for managing the behavioral manifestations of Sotos syndrome, highlighting the importance of a multidisciplinary approach to care for patients with this complex overgrowth condition.


  • Open Access

    Phenotypic spectrum and tumor risk in Simpson‐Golabi‐Behmel syndrome: Case series and comprehensive literature review

    by Alex F. Nisbet, Aravind Viswanathan, Andrew M. George, Pedro Arias, Steven D. Klein, Julian Nevado, Alejandro Parra, Patricia Pascual, Dominic J. Romeo, Jair Tenorio‐Castaño, et al.

    Simpson‐Golabi‐Behmel syndrome (SGBS) is a rare congenital overgrowth condition characterized by macrosomia, macroglossia, coarse facial features, and development delays. It is caused by pathogenic variants in the GPC3 gene on chromosome Xq26.2. Here, we performed a comprehensive literature review and phenotyping of known patients with molecularly confirmed SGBS and reviewed a novel cohort of 22 patients. Using these data, we characterized the tumor risk for Wilms tumor and hepatoblastoma to suggest appropriate screening for this patient population. In addition, we discuss the phenotypic overlap between SGBS and Beckwith‐Wiedemann Spectrum.


  • Open Access

    Expanded phenotype and cancer risk in patients with Beckwith–Wiedemann spectrum caused by CDKN1C variants

    by Andrew M. George, Aravind Viswanathan, Lyle G. Best, Caitlin Monahan, Maria Limmina, Arupa Ganguly, Jennifer M. Kalish

    Beckwith–Wiedemann spectrum (BWSp) is caused by genetic and epigenetic alterations on chromosome 11 that regulate cell growth and division. Considering the diverse phenotypic landscape in BWSp, the characterization of the CDKN1C molecular subtype remains relatively limited. Here, we investigate the role of CDKN1C in the broader BWSp phenotype. Notably, patients with CDKN1C variants appear to exhibit a different tumor risk than other BWSp molecular subtypes. We performed a comprehensive literature review using the search term “CDKN1C Beckwith” to identify 113 cases of patients with molecularly confirmed CDKN1C‐BWSp. We then assessed the genotype and phenotype in a novel cohort of patients with CDKN1C‐BWSp enrolled in the BWS Research Registry. Cardinal and suggestive features were evaluated for all patients reported, and tumor risk was established based on available reports. The most common phenotypes included macroglossia, omphalocele, and ear creases/pits. Tumor types reported from the literature included neuroblastoma, acute lymphocytic leukemia, superficial spreading melanoma, and intratubular germ cell neoplasia. Overall, this study identifies unique features associated with CDKN1C variants in BWSp, enabling more accurate clinical management. The absence of Wilms tumor and hepatoblastoma suggests that screening for these tumors may not be necessary, while the neuroblastoma risk warrants appropriate screening recommendations.